Bristol Myers Squibb is handing over the keys to its manufacturing site in Syracuse, NY, to South Korean company Lotte Biologics.
BMS announced this week that the sale of the facility is complete, with its divesture from the Syracuse manufacturing site a part of an effort to “evolve” the pharma’s manufacturing network. As part of the deal, all employees will continue to work for Lotte. BMS has also entered into a contract with Lotte to continue manufacturing some of its products at the facility.
Last year, South Korea’s Yonhap News Agency reported that the sale cost Lotte $160 million.
MilliporeSigma, Merck KGaA’s life science business in the US and Canada, will help Lotte in establishing its manufacturing capabilities in the US as well as with design and workforce training at the site.
According to the local news site, Syracuse.com Lotte also plans to invest around $77 million to expand its manufacturing capacity at the site.
Capital firms close Alcami acquisition
Alcami, the North Carolina-based CDMO, has officially been acquired by two venture capital firms.
In the deal, of which terms were not disclosed, GHO Capital Partners and The Vistria Group secure the acquisition of Alcami from funds affiliated with Ampersand Capital Partners and Madison Dearborn Partners. Both GHO and Vistria have a 50/50 controlling interest in the CDMO.
Alcami has five locations across the US and currently does contracting work in fill-finish and solid-dose manufacturing along with lab and storage services.
Polysciences introduces a new brand for bioprocessing
The Pennsylvania-based chemicals manufacturer Polysciences is planning a new brand specific to its offering for the bioprocessing market.
Dubbed Kyfora Bio, the brand will focus on the manufacture of lipids, polymers and other materials that are used in cell and gene therapies. Kyfora Bio will also have its own facility in the town of Horsham, PA, outside of Philadelphia. The 45,000-square-foot site will have manufacturing suites, offices and labs for quality control and Research and development.
“Kyfora Bio reflects Polysciences’ latest commitment to be the partner of choice in supplying key cGMP-compliant materials to the cell and gene therapy market,” Scott Knorr, president of Kyfora Bio, said in a statement.
Bruker nets majority ownership of Swiss CRO
The Brucker corporation has netted the majority ownership of Biognosys for an undisclosed amount. The transaction was not disclosed, but several investors sold shares to Brucker in another transaction.
The deal includes Bruker making new investments in the Swiss company, with Biognosys CEO Oliver Rinner and the leadership team continuing to manage the CRO. The deal will also give Biognosys a foot in the door to the US market and access to Bruker’s technology.
The partnership also includes Biognosys plans to open a CRO laboratory in the US, although the location and timeline have not been disclosed.
Currently, Biognosys offers mass spectrometry-based research services focusing on drug and protein discovery, among other services.